D R van Langenberg1, P Della Gatta2, B Hill2, E Zacharewicz2, P R Gibson3, A P Russell2. 1. Department of Gastroenterology & Hepatology, Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia. Electronic address: Daniel.van-Langenberg@monash.edu. 2. Centre of Physical Activity and Nutrition (C-PAN) Research, School of Exercise and Nutrition Science, Deakin University, Burwood, Victoria, Australia. 3. Department of Gastroenterology & Hepatology, Eastern Health Clinical School, Monash University, Box Hill, Victoria, Australia.
Abstract
BACKGROUND/AIMS: In Crohn's disease (CD), skeletal muscle mass and function are reduced compared to healthy controls, potentially resulting in disability. Mechanisms contributing to muscle impairment, and thus potential therapeutic targets, are poorly understood. This study aimed to measure and compare skeletal muscle size and molecular targets involved in skeletal muscle growth, in CD subjects and healthy controls. METHODS: CD (n=27) and healthy (n=22) subjects were recruited from the IBD outpatient clinic and via local advertisement respectively. Demographics and clinical data were collected via survey and interview. Quadriceps muscle cross-sectional area was measured using peripheral quantitative CT scanning. Levels of muscle hypertrophy and atrophy signalling targets using quantitative PCR and western blotting were measured in muscle biopsies. RESULTS: Muscle size was 14% lower (p=0.055) and a 54% lower phosphorylated:total (p:t) Akt ratio was measured in the muscle samples (p<0.05), indicating an attenuated muscle hypertrophy pathway in CD compared with controls. In those with CD, a lower p:t Akt ratio (<0.97) was associated with lower serum vitamin D3, lower physical activity indices (49 vs 64 mmol/L, 1.7 vs 2.2×10(6) accelerometer counts respectively, each p<0.05) and a trend towards lower serum ferritin levels (128 vs 322mg/L, p=0.07), compared with CD subjects with normal/high p:t Akt ratios. CONCLUSION: The reduced muscle mass in CD may be explained, in part, by impaired activation of muscle protein synthesis pathways, notably the IGF1-Akt pathway. Normal vitamin D levels and regular exercise may be protective in CD against this trend, though confirmatory longitudinal studies are needed.
BACKGROUND/AIMS: In Crohn's disease (CD), skeletal muscle mass and function are reduced compared to healthy controls, potentially resulting in disability. Mechanisms contributing to muscle impairment, and thus potential therapeutic targets, are poorly understood. This study aimed to measure and compare skeletal muscle size and molecular targets involved in skeletal muscle growth, in CD subjects and healthy controls. METHODS: CD (n=27) and healthy (n=22) subjects were recruited from the IBD outpatient clinic and via local advertisement respectively. Demographics and clinical data were collected via survey and interview. Quadriceps muscle cross-sectional area was measured using peripheral quantitative CT scanning. Levels of muscle hypertrophy and atrophy signalling targets using quantitative PCR and western blotting were measured in muscle biopsies. RESULTS: Muscle size was 14% lower (p=0.055) and a 54% lower phosphorylated:total (p:t) Akt ratio was measured in the muscle samples (p<0.05), indicating an attenuated muscle hypertrophy pathway in CD compared with controls. In those with CD, a lower p:t Akt ratio (<0.97) was associated with lower serum vitamin D3, lower physical activity indices (49 vs 64 mmol/L, 1.7 vs 2.2×10(6) accelerometer counts respectively, each p<0.05) and a trend towards lower serum ferritin levels (128 vs 322mg/L, p=0.07), compared with CD subjects with normal/high p:t Akt ratios. CONCLUSION: The reduced muscle mass in CD may be explained, in part, by impaired activation of muscle protein synthesis pathways, notably the IGF1-Akt pathway. Normal vitamin D levels and regular exercise may be protective in CD against this trend, though confirmatory longitudinal studies are needed.
Authors: Margaux J Barnes; Mary K Lynch; Molly D Lisenby; Traci Jester; Jeanine Maclin; Taylor Knight; Gordon Fisher; Barbara Gower Journal: J Pediatr Gastroenterol Nutr Date: 2019-03 Impact factor: 2.839
Authors: Jessica A Fitzpatrick; Sarah L Melton; Chu Kion Yao; Peter R Gibson; Emma P Halmos Journal: Nat Rev Gastroenterol Hepatol Date: 2022-05-16 Impact factor: 73.082
Authors: Kelly C Cushing; Hamed Kordbacheh; Michael S Gee; Avinash Kambadakone; Ashwin N Ananthakrishnan Journal: J Crohns Colitis Date: 2018-08-29 Impact factor: 9.071
Authors: Nik Sheng Ding; Daniel Tassone; Ibrahim Al Bakir; Kyle Wu; Alexander J Thompson; William R Connell; George Malietzis; Phillip Lung; Siddharth Singh; Chang-Ho Ryan Choi; Simon Gabe; John T Jenkins; Ailsa Hart Journal: J Crohns Colitis Date: 2022-09-08 Impact factor: 10.020
Authors: Jan Bilski; Agnieszka Mazur-Bialy; Dagmara Wojcik; Marcin Surmiak; Marcin Magierowski; Zbigniew Sliwowski; Robert Pajdo; Slawomir Kwiecien; Aleksandra Danielak; Agata Ptak-Belowska; Thomas Brzozowski Journal: Biomolecules Date: 2019-11-26
Authors: Jan Bilski; Bartosz Brzozowski; Agnieszka Mazur-Bialy; Zbigniew Sliwowski; Tomasz Brzozowski Journal: Biomed Res Int Date: 2014-04-30 Impact factor: 3.411
Authors: Robert Venning Bryant; Christopher G Schultz; Soong Ooi; Charlotte Goess; Samuel Paul Costello; Andrew D Vincent; Scott N Schoeman; Amanda Lim; Francis Dylan Bartholomeusz; Simon P L Travis; Jane Mary Andrews Journal: Nutrients Date: 2018-09-01 Impact factor: 5.717